$411M

Phase 2 ADC deals average this upfront payment in 2026

Antibody-drug conjugates (ADCs) continue to be one of the hottest modalities in biopharma licensing. With total deal values reaching $2.6B at Phase 2, ADCs command premium economics driven by platform versatility, validated targets, and next-generation linker-payload technologies.

Based on analysis of 1,600+ biopharma licensing deals from 2020-2026

Run Your Own Analysis Share on LinkedIn

More Deal Insights

58%

Radiopharmaceuticals command this premium over small molecules

$3.1B

Median total deal value for Phase 3 oncology assets in 2026

$1.6B

CAR-T cell therapy deals reach this total value at Phase 2

Get deal intelligence in your inbox

Weekly benchmarks, market signals, and deal analysis from 1,600+ transactions.

No spam. Unsubscribe anytime.

Benchmarks powered by 1,600+ real biopharma licensing deals

Try Solidus →